AU2015242495B2 - A therapeutic agent for use in the treatment of infections - Google Patents
A therapeutic agent for use in the treatment of infections Download PDFInfo
- Publication number
- AU2015242495B2 AU2015242495B2 AU2015242495A AU2015242495A AU2015242495B2 AU 2015242495 B2 AU2015242495 B2 AU 2015242495B2 AU 2015242495 A AU2015242495 A AU 2015242495A AU 2015242495 A AU2015242495 A AU 2015242495A AU 2015242495 B2 AU2015242495 B2 AU 2015242495B2
- Authority
- AU
- Australia
- Prior art keywords
- therapeutic agent
- acetyl
- nano
- micro
- donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 36
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 66
- 239000002105 nanoparticle Substances 0.000 claims abstract description 46
- 239000011859 microparticle Substances 0.000 claims abstract description 45
- 239000000969 carrier Substances 0.000 claims abstract description 40
- 239000002243 precursor Substances 0.000 claims abstract description 39
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 37
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000002145 thermally induced phase separation Methods 0.000 claims abstract description 15
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241001465754 Metazoa Species 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000011065 in-situ storage Methods 0.000 claims abstract description 7
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 4
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 33
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 claims description 20
- 229940045872 sodium percarbonate Drugs 0.000 claims description 20
- FRPJTGXMTIIFIT-UHFFFAOYSA-N tetraacetylethylenediamine Chemical compound CC(=O)C(N)(C(C)=O)C(N)(C(C)=O)C(C)=O FRPJTGXMTIIFIT-UHFFFAOYSA-N 0.000 claims description 19
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- -1 buckyballs Substances 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 claims description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 6
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 6
- VPVSTMAPERLKKM-UHFFFAOYSA-N glycoluril Chemical compound N1C(=O)NC2NC(=O)NC21 VPVSTMAPERLKKM-UHFFFAOYSA-N 0.000 claims description 6
- 229960001922 sodium perborate Drugs 0.000 claims description 6
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 4
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 claims description 4
- GMLREHXYJDLZOU-LEPYJNQMSA-N 3-Acetylmorphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GMLREHXYJDLZOU-LEPYJNQMSA-N 0.000 claims description 3
- 239000004160 Ammonium persulphate Substances 0.000 claims description 3
- SKORSNZZDZSCKK-UHFFFAOYSA-N C(C)(=O)NC(N(C(C)=O)C(C)=O)=O Chemical compound C(C)(=O)NC(N(C(C)=O)C(C)=O)=O SKORSNZZDZSCKK-UHFFFAOYSA-N 0.000 claims description 3
- QISSLHPKTCLLDL-UHFFFAOYSA-N N-Acetylcaprolactam Chemical compound CC(=O)N1CCCCCC1=O QISSLHPKTCLLDL-UHFFFAOYSA-N 0.000 claims description 3
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 claims description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012346 acetyl chloride Substances 0.000 claims description 3
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 claims description 3
- 235000019395 ammonium persulphate Nutrition 0.000 claims description 3
- ZJRXSAYFZMGQFP-UHFFFAOYSA-N barium peroxide Chemical compound [Ba+2].[O-][O-] ZJRXSAYFZMGQFP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims description 3
- BHDAXLOEFWJKTL-UHFFFAOYSA-L dipotassium;carboxylatooxy carbonate Chemical compound [K+].[K+].[O-]C(=O)OOC([O-])=O BHDAXLOEFWJKTL-UHFFFAOYSA-L 0.000 claims description 3
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 claims description 3
- 125000001976 hemiacetal group Chemical group 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- HPGPEWYJWRWDTP-UHFFFAOYSA-N lithium peroxide Chemical compound [Li+].[Li+].[O-][O-] HPGPEWYJWRWDTP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- UJQLDFMZDSDZEY-UHFFFAOYSA-N n-(acetylcarbamoyl)acetamide Chemical compound CC(=O)NC(=O)NC(C)=O UJQLDFMZDSDZEY-UHFFFAOYSA-N 0.000 claims description 3
- GKRZNOGGALENQJ-UHFFFAOYSA-N n-carbamoylacetamide Chemical compound CC(=O)NC(N)=O GKRZNOGGALENQJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910021392 nanocarbon Inorganic materials 0.000 claims description 3
- 150000002976 peresters Chemical class 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229940083542 sodium Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 abstract description 5
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 230000001590 oxidative effect Effects 0.000 abstract description 4
- 239000003139 biocide Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000011068 loading method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical class O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 102100022258 Disks large homolog 5 Human genes 0.000 description 1
- 101100063489 Homo sapiens DLG5 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000012899 de-mixing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1405874.7 | 2014-04-01 | ||
| GBGB1405874.7A GB201405874D0 (en) | 2014-04-01 | 2014-04-01 | A therapeutic agent for use in the treatment of infections |
| GBGB1415063.5A GB201415063D0 (en) | 2014-04-01 | 2014-08-26 | A therapeutic agent for use in the treatment of infections |
| GB1415063.5 | 2014-08-26 | ||
| PCT/GB2015/000100 WO2015150722A1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015242495A1 AU2015242495A1 (en) | 2016-10-06 |
| AU2015242495B2 true AU2015242495B2 (en) | 2020-04-30 |
Family
ID=50737835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015242495A Active AU2015242495B2 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9913805B2 (enExample) |
| EP (2) | EP3125874B1 (enExample) |
| JP (1) | JP6573286B2 (enExample) |
| KR (2) | KR102359855B1 (enExample) |
| CN (1) | CN106456557B (enExample) |
| AU (1) | AU2015242495B2 (enExample) |
| CA (1) | CA2943431C (enExample) |
| DK (1) | DK3125874T3 (enExample) |
| ES (2) | ES2953755T3 (enExample) |
| GB (3) | GB201405874D0 (enExample) |
| IL (1) | IL247969B (enExample) |
| MX (1) | MX2016012757A (enExample) |
| NZ (1) | NZ724298A (enExample) |
| SG (2) | SG11201608093WA (enExample) |
| WO (1) | WO2015150722A1 (enExample) |
| ZA (1) | ZA201606387B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201405874D0 (en) * | 2014-04-01 | 2014-05-14 | Aga Nanotech Ltd | A therapeutic agent for use in the treatment of infections |
| CN107281220B (zh) * | 2016-03-31 | 2020-02-14 | 中国科学院上海硅酸盐研究所 | 一种介孔氧化硅基活性氧(ros)放疗增敏剂及其制备方法 |
| CN106860032B (zh) * | 2016-10-25 | 2021-04-09 | 咏达生医材料股份有限公司 | 一种气态皮肤供氧美白产品及其应用 |
| JP2019194162A (ja) * | 2018-05-01 | 2019-11-07 | ツァ ギャリー | 肌の酸素供給による美白及び加熱機能を備えた通気性材料 |
| JP7372706B2 (ja) | 2019-10-10 | 2023-11-01 | アルファ タウ メディカル リミテッド | 放射線治療源の湿式調製 |
| GB2592911B (en) * | 2020-02-28 | 2023-06-28 | Aga Nanotech Ltd | A plasma-activatable wound dressing for treatment of infections |
| GB202005556D0 (en) | 2020-04-16 | 2020-06-03 | Aga Nanotech Ltd | Covid face mask |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060088498A1 (en) * | 2004-10-27 | 2006-04-27 | Truox, Inc. | Anti-microbial composition using in-situ generation of an oxidizing agent |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997007777A1 (en) * | 1995-08-15 | 1997-03-06 | Robert Eric Montgomery | Peroxidase-activating oral compositions |
| DE59912558D1 (de) * | 1999-07-02 | 2005-10-20 | Cognis Ip Man Gmbh | Mikrokapseln - IV |
| AU4477001A (en) * | 2000-04-18 | 2001-10-30 | Peptron Inc. | Injectable sustained release pharmaceutical composition and processes for preparing the same |
| KR100342746B1 (ko) * | 2000-06-27 | 2002-07-03 | 김찬화 | 인슐린의 방출제어제제 및 그 방법 |
| GB0411304D0 (en) * | 2004-05-21 | 2004-06-23 | Fellows Adrian N | An antimicrobial composition |
| EP1919507A2 (en) * | 2005-08-04 | 2008-05-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
| KR20070071225A (ko) * | 2005-12-29 | 2007-07-04 | 애경산업(주) | 치아 미백용 조성물 |
| GB0711952D0 (en) | 2007-06-20 | 2007-08-01 | King S College London | Microspheres |
| WO2009108407A1 (en) * | 2008-02-25 | 2009-09-03 | The University Of North Carolina At Charlotte Office Of Technology Transfer | Biodegradable therapeutic nanoparticles containing an antimicrobial agent |
| CA2730995C (en) * | 2008-07-17 | 2016-11-22 | Micell Technologies, Inc. | Drug delivery medical device |
| US8969282B2 (en) * | 2009-02-05 | 2015-03-03 | American Sterilizer Company | Low odor, hard surface sporicide |
| KR101136028B1 (ko) * | 2009-04-27 | 2012-04-18 | 한양대학교 산학협력단 | 다공성 마이크로스피어의 제조방법 |
| US8889161B2 (en) * | 2009-04-27 | 2014-11-18 | Premier Dental Products Company | Microencapsulated compositions and methods for tissue mineralization |
| NZ600269A (en) * | 2009-05-20 | 2014-02-28 | Dec Int Nz Ltd | Delivery device for treatment of mastitis |
| US9187594B2 (en) * | 2010-02-09 | 2015-11-17 | The Regents Of The University Of Michigan | Nano-fibrous microspheres and methods for making the same |
| HUE033386T2 (en) * | 2010-07-09 | 2017-11-28 | Innocore Tech B V | Release of Biodegradable Phase Separated Segmented Multiblock Copolymers and Biologically Active Polypeptides |
| EP2611466B1 (en) * | 2010-08-30 | 2019-06-12 | President and Fellows of Harvard College | Shear controlled release of thrombolytic therapies for stenotic lesions |
| GB201405874D0 (en) * | 2014-04-01 | 2014-05-14 | Aga Nanotech Ltd | A therapeutic agent for use in the treatment of infections |
-
2014
- 2014-04-01 GB GBGB1405874.7A patent/GB201405874D0/en not_active Ceased
- 2014-08-26 GB GBGB1415063.5A patent/GB201415063D0/en not_active Ceased
-
2015
- 2015-03-24 KR KR1020167030614A patent/KR102359855B1/ko active Active
- 2015-03-24 CA CA2943431A patent/CA2943431C/en active Active
- 2015-03-24 AU AU2015242495A patent/AU2015242495B2/en active Active
- 2015-03-24 EP EP15714598.8A patent/EP3125874B1/en active Active
- 2015-03-24 DK DK15714598.8T patent/DK3125874T3/da active
- 2015-03-24 US US15/126,511 patent/US9913805B2/en active Active
- 2015-03-24 MX MX2016012757A patent/MX2016012757A/es active IP Right Grant
- 2015-03-24 SG SG11201608093WA patent/SG11201608093WA/en unknown
- 2015-03-24 CN CN201580018976.4A patent/CN106456557B/zh active Active
- 2015-03-24 ES ES20215977T patent/ES2953755T3/es active Active
- 2015-03-24 KR KR1020227003691A patent/KR102482597B1/ko active Active
- 2015-03-24 SG SG10201801524PA patent/SG10201801524PA/en unknown
- 2015-03-24 ES ES15714598T patent/ES2855985T3/es active Active
- 2015-03-24 JP JP2017503081A patent/JP6573286B2/ja active Active
- 2015-03-24 EP EP20215977.8A patent/EP3848022B1/en active Active
- 2015-03-24 WO PCT/GB2015/000100 patent/WO2015150722A1/en not_active Ceased
- 2015-03-24 GB GB1617053.2A patent/GB2538923B/en active Active
- 2015-03-24 NZ NZ724298A patent/NZ724298A/en not_active IP Right Cessation
-
2016
- 2016-09-15 ZA ZA2016/06387A patent/ZA201606387B/en unknown
- 2016-09-22 IL IL247969A patent/IL247969B/en active IP Right Grant
-
2018
- 2018-01-18 US US15/874,552 patent/US10933026B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060088498A1 (en) * | 2004-10-27 | 2006-04-27 | Truox, Inc. | Anti-microbial composition using in-situ generation of an oxidizing agent |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10933026B2 (en) | Method for manufacturing a therapeutic agent for use in the treatment of infections | |
| Yuan et al. | Near-infrared light-triggered nitric-oxide-enhanced photodynamic therapy and low-temperature photothermal therapy for biofilm elimination | |
| Li et al. | Biguanide-derived polymeric nanoparticles kill MRSA biofilm and suppress infection in vivo | |
| Lakshminarayanan et al. | Recent advances in the development of antimicrobial nanoparticles for combating resistant pathogens | |
| Gupta et al. | Use of nanotechnology in antimicrobial therapy | |
| Qayyum et al. | Nanoparticles vs. biofilms: a battle against another paradigm of antibiotic resistance | |
| AU2015315108B2 (en) | Antimicrobial and biologically active polymer composites and related methods, materials and devices | |
| Kasimanickam et al. | Prevention and treatment of biofilms by hybrid-and nanotechnologies | |
| Hlaing et al. | S-Nitrosoglutathione loaded poly (lactic-co-glycolic acid) microparticles for prolonged nitric oxide release and enhanced healing of methicillin-resistant Staphylococcus aureus-infected wounds | |
| Brar et al. | Nanotechnology: a contemporary therapeutic approach in combating infections from multidrug-resistant bacteria | |
| Chen et al. | Polymeric nanoplatforms for the delivery of antibacterial agents | |
| Shende et al. | Polymeric nanodroplets: an emerging trend in gaseous delivery system | |
| Sofokleous et al. | Sustained antimicrobial activity and reduced toxicity of oxidative biocides through biodegradable microparticles | |
| Wang et al. | Research progress of stimulus-responsive antibacterial materials for bone infection | |
| Mahavir et al. | Application of nanostructures in antimicrobial therapy | |
| Chan et al. | Applications of nanoparticles for antimicrobial activity and drug delivery | |
| Safaran et al. | Advances in polymeric and non-polymeric nanocarriers for the magnified delivery of levofloxacin against bacterial infection | |
| HK40052395A (en) | A therapeutic agent for use in the treatment of infections | |
| Ahmed Mousa et al. | SPANLASTICS: A Unique Formulation Strategy in The Delivery of Pharmaceuticals-Carbapenems as a Model. | |
| Feng et al. | Bacteria-responsive drug release platform for the local treatment of bacterial vaginosis | |
| HK1233167B (zh) | 在感染的治疗中使用的治疗剂 | |
| Abbot et al. | Micelles transforming modern medicine: a comprehensive review on the role of micellar physicochemical properties in improving the flavonoid bioavailability and neomycin efficacy | |
| HK1233167A1 (en) | A therapeutic agent for use in the treatment of infections | |
| Gowtham et al. | Recent advancements of carbon quantum dots for biological applications | |
| Barathe et al. | Nanomaterial-Mediated Delivery of Antimicrobial Agents:‘The Nanocarriers’ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |